Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

Riding on a surge in global demand for its patented obesity and diabetes medicines Ozempic, Wegovy and Rybelsus, ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

When a patient with obesity reports a new symptom, many physicians are quick to focus on the excess weight without exploring alternative reasons. Wrong approach, experts said.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Novo Nordisk (NVO) ended the recent trading session ... to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of ...

Novo Nordisk (NVO) ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...